Abstract: Disclosed are oral dosage forms containing a Ras antagonist including FTS and structural analogs thereof, and at least one pharmaceutically acceptable excipient other than a cyclodextrin, and methods of orally administering same to treat diseases and disorders responsive to the Ras antagonists.

Abstract: The present invention is directed to a stabilized anti-dandruff composition comprising about 10 wt. % to about 40 wt. % of an insoluble anti-dandruff agent, about 6 wt. % to about 12 wt. % of a stabilizer, less than about 1 wt. % of a preservative, and about 0.5 wt. % to about 1 wt. % of a neutralizer, and water. In an embodiment of the present invention, it is directed to a stabilized anti-dandruff composition comprising about 10 wt. % to about 25 wt. % of a zinc-containing layered material, about 6 wt. % to about 12 wt. % of a stabilizer, less than about 1 wt. % of a preservative, and about 0.5 wt. % to about 1 wt. % of a neutralizer, and water.

Abstract: The present invention relates to home and personal care compositions comprising a silicone oil-in-water emulsion stabilized by a protein or peptide and at least one home and/or personal care ingredient. Such compositions tend to provide desirable characteristics for the care and conditioning of hair, skin and fabric.

Abstract: A composition comprising a glyceryl salicylate compound and/or a glycol salicylate compound. The compositions can be used to reduce the amount of moisture evaporated from skin, protect the skin from UV light, and treat aged or damaged skin.

Abstract: Optically active polymers that are composed of monomer residues derived from chiral pre-polymerized monomers, which maintain the chirality of the pre-polymerized monomers upon polymerization are disclosed. These polymers can be composed of monomer residues that are derived from readily available chiral monomers and can be designed to have pre-determined characteristics such as chirality, biodegradability and functionality. Uses of these polymers as therapeutically active agents, and/or as carriers of therapeutically active agents, for delivering the active agents to a targeted bodily site and/or for a sustained release of the active agent, are further disclosed. Also disclosed are processed of preparing the polymers, compositions and medical devices containing the polymers, and conjugates of these polymers and various agents.

Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

Abstract: The invention relates to the use of and mainly novel compounds of the formula I wherein the moieties are as defined in the description, which are useful as farnesyl pyrophosphate synthase modulators and e.g. in the treatment of proliferative diseases.

Abstract: This disclosure relates to a pharmaceutical composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5?-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that is a serotonin metabolite.

Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.

Abstract: A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is greater than the effect of the individual components alone. The composition includes a biologically effective amount of vitamin E for inhibiting propagation of lipid peroxidation that contributes to hearing loss. The composition also includes a biologically effective amount of a salicylate for reducing hydroxyl radicals that contribute to hearing loss. A method of treating hearing loss includes the step of internally administering the composition, as described above, to a mammal within three days of trauma to a middle or inner ear of the mammal. In other words, the composition is effective even when administered as late as three days after trauma to a middle or inner ear of a mammal.

Abstract: A pharmaceutical composition comprising at least 0.1 ?mol of formaurindicarboxylic acid or its derivatives in 1 kg of pharmaceutically acceptable carrier. The pharmaceutical composition of claim 1 wherein the composition is in the form of solution prepared using aqueous alcali or water.

Abstract: A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R1 and R2 are independently C1-30alkyl(R3, R3?, R4, R5, W and “n” are as defined in claim 1) in particular where the compound is S-dimethylarsinoglutathione, N-(2-S-dimethylarsinothiopropionyl)glycine, 2-amino-3-(dimethylarsino)thio-3-methylbutanoic acid, S-dimethylarsino-thiosuccinic acid or S-dipropylarsino-1-thioglycerol.

Abstract: An improved composition for skin cleansing and protection is disclosed. The composition contains an effective amount of at least one alpha-hydroxyl acid or a pharmaceutically acceptable salt thereof, at least one base, one surfactant and one skin protectant. Various additives and excipients may be included in the formulation. The improved composition disclosed herein achieves a higher bacteria killing rate and shows longer action duration. The disclosed composition is capable of penetrating deep into the skin which allows for delivery of more anti-microbials to sites that are at a higher risk of being infected. Various modifications of the improved composition are also disclosed.

Abstract: The present invention is directed to skin treatment formulations having salicylic acid and other secondary ingredients. The secondary ingredients may include: non-comedogenic essential oils and plant extracts and sebum reducing agents. Salicylic acid and the secondary ingredients are provided in amounts effective to provide a sufficiently aggressive skin treatment for unclogging pores and reducing inflammation, while maintaining levels of sebum on the exterior of the skin to form an operative water barrier on the skin and hair. Additionally, a method is provided that unclogs pores, reduces inflammation, and controls levels of sebum on the exterior of the skin to maintain an operative water barrier on the skin and hair. The method may include, applying a sufficiently aggressive product comprising salicylic acid, non-comedogenic plant extracts and essential oils, and a sebum reducing agent to hair and its surrounding areas.

Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.

Abstract: A pharmaceutical composition comprising at least 0.1 ?mol of formaurindicarboxylic acid or its derivatives in 1 kg of pharmaceutically acceptable carrier. The pharmaceutical composition of claim 1 wherein the composition is in the form of solution prepared using aqueous alcali or water.

Abstract: The invention is generally directed to a drug-release composition that contains drug-linker-drug compound that is combined with another therapeutic agent that can be an antirestenotic agent. The therapeutic agent can be partially bound to the drug-linker-drug compound, miscible with the drug-linker-drug compound, combined with the drug-linker-drug compound at various ratios, and tuned to control the release of drugs to a tissue in need thereof.

Abstract: A method for the topical treatment of skin aging and acne and the improvement of skin appearance is disclosed. Compositions for use in this method and a kit containing such compositions are also disclosed. In some of the embodiments of the invention, either one, or both, of the acid composition and neutralizing composition useful in the method for the topical treatment of skin aging and acne and the improvement of skin appearance are of low viscosity. The compositions and methods are effective but gentle enough to be suitable for daily home use by the consumer.

Abstract: There is described a pharmaceutical composition for controlled release of an active compound wherein the active compound is selected from the group comprising tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof for the treatment or alleviation of depression. More particularly, there is described an abuse resistant pharmaceutical composition for the treatment of inter alia, depression and controlled release pharmaceutical compositions of related thereto.

Abstract: The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.

Abstract: A method of treating hair comprising applying a hair building solid agent for use on or with one or more of hair, skin and hair building solids for altering and/or maintaining the electrostatic charge of the hair and/or skin such that it has a substantially negative polarity. The method further comprises applying hair building solids to hair before and/or during and/or after applying the hair building solid agent. The hair building solid agent is applied as a spray on to the hair and/or skin and/or hair building solid.

Abstract: The invention provides a long acting curcumin derivative, preparation method and pharmaceutical use thereof, wherein said long acting curcumin derivative having the general structural formula disclosed herein, wherein R1 and R2 are hydrogen or methoxyl; R3 and R4 are each independently selected from C1-C50 alkyl. Compared with cuminoids, the inventive long acting curcumin derivative has a better release effect, a higher bioavailability and pharmaceutical activity, and thus can be useful for the treatment of diseases such as depression and cancer.

Abstract: Disclosed are methods of screening for an autism spectrum disorder, compositions that inhibit the release of molecules that disrupt the blood-brain barrier, compositions for treating autism spectrum disorders, and methods of treating autism spectrum disorders.

Abstract: A topical pain reliever and method of making the same is disclosed. The topical pain reliever may comprise effective amounts of water, glycerine, analgesic agent such as salicylic acid or a derivative thereof, and alcohol. The method of making the topical pain reliever may maintain the analgesic agent in suspension within a solution. The topical pain reliever may be applied to the skin of a user to provide pain relief without ingestion of the composition, thereby potentially avoiding adverse side effects.

Abstract: A clear soft vegetarian dosage capsule comprising a first and second biphasic film. The first biphasic film has a plurality of first reservoirs and further comprises a polysaccharide, a seaweed extract, a rheology modifier, a buffer and a plasticizer. The second biphasic film has a plurality of second reservoirs having a formulation identical to the first film to ensure a sealing engagement. A dosage amount is disposed in each of the plurality of the reservoirs forming a plurality of filled reservoirs. The dosage amount is an emulsion, oil, hydrophilic liquid. The first film is extruded or overlaid with the second film allowing each of the plurality of second reservoirs to overlay the filled reservoirs and sealed with pressure and a fusion temperature slightly less than the melting point of the first and second films forming clear soft vegetarian dosage capsules that are blown dry, bonding moisture to the polysaccharide.

Abstract: The invention provides a solvating system for the removal of biofilms which solvates the extracellular polysaccharide matrix holding it to a surface. The aqueous solvating system comprises water, a metal ion sequestering agent, and a solvating agent for an extracellular polysaccharide matrix, which is gentle enough to be used directly on human tissues, but which may also be used on hard or soft non-tissue surfaces to breakdown, and/or remove biofilms.

Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of athlete's foot (tinea pedis) and nail fungus (onychomycosis). The invention involves an anhydrous composition containing a therapeutically effective amount of salicylic acid. Repeated applications of the resulting formula over a 4-12 week period resolve most infections without the use of systemic drugs.

Abstract: Rosiglitazone, 5-ASA or structurally analogous Compounds according to the general formula (I): or Compounds according to the general formula (Ia): For the induction of CAMP expression in tissues having PPAR-gamma receptors. Such tissues include epithelia or mucosae tissue having PPAR-gamma receptors and of particular interest is CAMP expression in the gut.

Abstract: Disclosed are methods for reducing the extent of myocardial ischemia/reperfusion injury, comprising administering to a human prior to reperfusion of the ischemic myocardium or pre-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof. Methods of treating ischemia/reperfusion injury, comprising administering to a human after reperfusion of the ischemic myocardium or post-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof are also disclosed.

Abstract: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.

Abstract: The invention relates to a method of treating acne by the topical administration of an acne active ingredient in the presence of a) an anhydrous composition comprising a component that in the presence of water generates heat, and b) water. The invention also relates to an acne treatment kit comprising a first composition which is anhydrous and comprises a component that in the presence of water generates heat on the skin to which it is applied and a second composition which comprises an aqueous carrier, at least one of said compositions comprising an acne active ingredient, said compositions being stored in isolation from each other and being capable of generating heat when they are combined.

Abstract: The present invention provides for compositions and methods that may offer protection from irritants as well as antimicrobial protection. Preferred embodiments of the invention include topical antimicrobial compositions that lack conventional antibiotics or preservatives, wherein the antimicrobial benefit is created by essential oils (or their active ingredients), emollient solvents and, in some instances, anti-inflammatory agents.

Abstract: Active compound combinations are disclosed which comprise (A) a dithiino-tetracarboximide of formula (I) and a further insecticidally active compound (B). Methods for controlling animal pests such as insects and/or unwanted acarids and for curatively or preventively controlling the phytopathogenic fungi of plants or crops are also disclosed as well as the use of a composition according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed.

Abstract: The present patent application relates to a composition for topical application in the form of an oil-in-water emulsion comprising an oily phase dispersed in an aqueous phase, characterized in that it comprises at least one noncrosslinked amphiphilic polymer, the globules of the said emulsion exhibiting a mean size ranging from 15 to 500 microns and the oily phase being present in an amount of less than 35% by weight, with respect to the total weight of the composition.

Abstract: A method of treating neoplastic disease in a human or animal patient is provided comprising administering to the patient an anti-neoplastic effective amount of a composition comprising as the sole pharmaceutically active components (a) copper gluconate or copper orotate; (b) sodium salicylate; (c) vitamin C; (d) manganese gluconate or manganese orotate; and optionally one or more of (e) iron gluconate or iron orotate; (f) sublimed sulphur; and (g) zinc gluconate or zinc orotate.

Abstract: A pressure sensitive adhesive for medicinal application purposes, based on ethylene-vinyl acetate copolymers is characterized in that it contains as polymer component (A) an ethylene-vinyl acetate copolymer or a combination of at least two ethylene-vinyl acetate copolymers, and as component (B) an adhesive resin or a combination of adhesive resins at a portion of up to 55%-wt, relative to the sum of components (A) and (B) without active substances or other auxiliary substances.

Abstract: The present invention relates to salts of Memantine and COX-INHIBITORs, their crystal form, the processes for preparation of the same and their uses for the treatment of various disorders, including pain.

Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, compound of the formula (I): wherein n is 1 or 2; m is 0, 1, 2, 3, 4, 5, 6, 7 or 8; q is 0 or 1; t is 0 or 1; R1 is alkyl having from 1 to 3 carbon atoms; R2 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; R3 and R4 together are alkyl having two or three carbon atoms; or R3 and R4 are the same as each other and each is methyl or ethyl; R5 is hydrogen or alkyl having from one to six carbon atoms.

Abstract: Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus.

Abstract: A novel method for making and using topical dermatological solution for external use which is effective in treating dermatological disorders. The methods include administering a therapeutically effective amount of a topical dermatological solution comprising pre-mixed agents which can affect a variety of inflammatory conditions of the skin thus treating a variety of minor skin irritations resulting from an array of causes such as dermatitis, insect bites, skin rash, plant poisoning, acne, pimples, folliculitis, sunburn, burns, and the like. The method for making this unique curative solution includes mixing particular proportions of aspirin, white vinegar, table salt, and baking soda. The present invention further provides a topical dermatological solution and a method for applying the topical dermatological solution to the skin from a single dispensing and applicator sheet, wherein said solution is released from the sheet and applied to the afflicted skin area.

Abstract: Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid to affected areas of the intestine. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

Abstract: A low ether gel composition for application to skin comprising a keratolytic agent, in particular salicylic acid, and comprising a nitrocellulose and one or more volatile ingredients, which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin; methods of treating using such compositions, and dispensers containing such compositions.

Abstract: The invention relates to substituted thioacetic acid salicylate derivatives; compositions comprising an effective amount of a substituted thioacetic acid salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a substituted thioacetic acid salicylate derivative.

Abstract: A biodegradable microfiber absorbent comprises a substantially homogeneous mixture of at least one hydrophilic polymer and at least one biodegradable polymer. The absorbent can be prepared by an electro hydrodynamic spinning of a substantially homogeneous polymer mixture. Medical dressings for burns and wounds, cavity dressings, drug delivery patches, face masks, implants, drug carriers that comprises at least one microfiber electrospun from a polymer mixture are provided. The dressings can have variable water vapor penetration characteristics and variable biodegradation times.

Abstract: A topical treatment for skin disorders and diseases comprising a combination of at least one antifungal agent and at least one hydroxy acid agent having a pH?pKa value of 0.5 or more formulated into shampoos, creams, lotions, gels, sprays, foams, pads, films, patches, and solutions for treatment of skin disorders and diseases in both humans and animals.

Abstract: A delivery device including at least one stinging capsule and methods of use are described.

Abstract: A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25° C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use.

Abstract: The present application describes a composition comprising a neuroprotective effective amount of an antioxidant acetylsalicylic acid maltol ester (AME).

Abstract: The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound.

Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.